-transparent.png){kind=logo}
The present authors investigated the excretion, distribution and pharmacokinetics of the novel potential antirheumatic agent flobufen and its active metabolite after p.o. and i.v. doses of 2, 10 and 50 mg/kg administered to rats. The drug is resorbed well from the digestive tract and mostly it is metabolized to the principal metabolite M, which is only slowly excreted from the organism mainly by renal clearance. Within the whole dose range the kinetics of the drug is linear. Binding of flobufen and M to proteins is high (95-99%). The highest concentrations of radioactive metabolites (mostly M) were found in the plasma, liver, lungs, kidneys, connective tissue and inflammatory foci. The penetration of metabolites through the placenta and excretion in human milk are relatively important.
R Lapka, and
A Brejcha, and
S Smolík, and
Z Franc
January 1990,
Drug metabolism and disposition: the biological fate of chemicals,
R Lapka, and
A Brejcha, and
S Smolík, and
Z Franc
September 1985,
Journal of pharmaceutical sciences,
R Lapka, and
A Brejcha, and
S Smolík, and
Z Franc
January 1995,
Chirality,
R Lapka, and
A Brejcha, and
S Smolík, and
Z Franc
August 1994,
American journal of therapeutics,
R Lapka, and
A Brejcha, and
S Smolík, and
Z Franc
January 1993,
European journal of clinical pharmacology,
R Lapka, and
A Brejcha, and
S Smolík, and
Z Franc
April 1976,
Research communications in chemical pathology and pharmacology,
R Lapka, and
A Brejcha, and
S Smolík, and
Z Franc
July 1988,
Clinical pharmacology and therapeutics,
R Lapka, and
A Brejcha, and
S Smolík, and
Z Franc
June 1983,
Journal of pharmacobio-dynamics,
R Lapka, and
A Brejcha, and
S Smolík, and
Z Franc
July 1991,
Xenobiotica; the fate of foreign compounds in biological systems,
R Lapka, and
A Brejcha, and
S Smolík, and
Z Franc
April 1995,
Journal of clinical pharmacology,
